Quick Answer
Mirum Pharmaceuticals, Inc. reported Stockholders Equity of $314.69 million for fiscal year 2025.
Mirum Pharmaceuticals, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $314.69M | +39.5% |
| 2024 | $225.64M | -9.3% |
| 2023 | $248.67M | +75.1% |
| 2022 | $142.04M | +18.2% |
| 2021 | $120.21M | -30.1% |
| 2020 | $172.09M | +32.0% |
| 2019 | $130.35M | +852.9% |
| 2018 | -$17.31M | — |
| 2018 | $0.00 | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $292.05M | +25.9% | +14.5% |
| June 30, 2025 | $255.16M | +11.4% | +9.4% |
| March 31, 2025 | $233.26M | -0.6% | +3.4% |
| December 31, 2024 | $225.64M | -9.3% | -2.8% |
| September 30, 2024 | $232.02M | -13.8% | +1.3% |
| June 30, 2024 | $228.99M | +191.3% | -2.4% |
| March 31, 2024 | $234.60M | +66.2% | -5.7% |
| December 31, 2023 | $248.67M | +75.1% | -7.6% |
- Mirum Pharmaceuticals, Inc. showed an increase of +39.5% in Stockholders Equity compared to the prior fiscal year.
- The most recent figure is from Mirum Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: